Posted on

Necrotizing Enterocolitis Market to Register Stunning Growth at a CAGR of 26% During the Forecast Period (2026–2036) | DelveInsight

The necrotizing enterocolitis market is witnessing steady growth, primarily driven by the increasing incidence of preterm births worldwide, as premature infants are at the highest risk of developing NEC. Rising awareness among healthcare providers regarding early diagnosis and preventive care is further supporting market expansion. Additionally, ongoing research activities focused on novel therapeutics such as IBP-9414 (Infant Bacterial Therapeutics), STMC-106 (Siolta Therapeutics), ST266 (Noveome Biotherapeutics), Protego-PD (Plakous Therapeutics), and others, probiotics, stem cell therapies, and targeted interventions are creating significant growth opportunities. 

The necrotizing enterocolitis market is witnessing steady growth, primarily driven by the increasing incidence of preterm births worldwide, as premature infants are at the highest risk of developing NEC. Rising awareness among healthcare providers regarding early diagnosis and preventive care is further supporting market expansion. Additionally, ongoing research activities focused on novel therapeutics such as IBP-9414 (Infant Bacterial Therapeutics), STMC-106 (Siolta Therapeutics), ST266 (Noveome Biotherapeutics), Protego-PD (Plakous Therapeutics), and others, probiotics, stem cell therapies, and targeted interventions are creating significant growth opportunities.

By sf-admin
Posted on

AMG Critical Materials N.V. Successfully Closes the Acquisition of Zinnwald Lithium Plc.

Amsterdam, 27 July 2026 (Regulated Information) — AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) is pleased to confirm the transaction initially announced on May 14, 2026 to acquire the remaining c. 71% ownership interest in Zinnwald Lithium Plc. has been successfully completed as of July 27, 2026 in accordance with the announced terms. The Zinnwald Lithium shares are expected to be converted into AMG shares and credited to Zinnwald shareholders between July 29, 2026, and August 10, 2026.

By sf-admin
Posted on

SNDL Announces Completion of Parallel Asset Acquisition and Positions for Nasdaq-Consolidated U.S. Medical Cannabis Operations

EDMONTON, Alberta, July 27, 2026 (GLOBE NEWSWIRE) — SNDL Inc. (NASDAQ: SNDL, CSE: SNDL) (“SNDL” or the “Company”) today announced the completion of the acquisition of certain assets of Surterra Holdings, Inc. and certain of its affiliates (collectively, “Parallel”), a U.S. vertically integrated cannabis operator with state-licensed operations in Florida, Texas and Massachusetts (the “Parallel Transaction”). The Parallel Transaction was previously announced on April 29, 2026.

By sf-admin
Posted on

TD Bank Group Invests $1 Million to Advance Research in Women’s Brain Health and Menopause Care

TD’s donation to Sinai Health Foundation will expand a novel study investigating whether menopausal hormone therapy can help address migraine and brain fog symptoms experienced during menopause. 

TD’s donation to Sinai Health Foundation will expand a novel study investigating whether menopausal hormone therapy can help address migraine and brain fog symptoms experienced during menopause.

By sf-admin
Posted on

XM Partner Code PY8GQ Launched By VistaForex

NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) — XM Partner Code PY8GQ is now available through a new partnership with VistaForex, offering traders a compelling 100% deposit bonus along with additional promotional advantages designed to support successful trading journeys.

By sf-admin
Posted on

Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update – Correction

Kennewick, WA, July 27, 2026 (GLOBE NEWSWIRE) — Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™, is pleased to share this update on the meaningful advancements the company has made across our core initiatives. Our team remains focused on advancing Precision Radionuclide Therapy™ (PRnT), our proprietary yttrium-90-based injectable hydrogel technology, to deliver accessible treatments for cancerous tumors in both humans (RadioGel®) and animals (IsoPet®).

By sf-admin